Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases

Drug Monitoring ◽

Therapeutic Drug ◽

Tnf Α ◽

Bowel Diseases ◽

New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases

British Journal of Clinical Pharmacology ◽

10.1111/bcp.13845 ◽

2019 ◽

Vol 85 (4) ◽

pp. 722-728 ◽

Cited By ~ 1

Author(s):

Benjamin Nemoz ◽

David Ternant ◽

Sébastien Bailly ◽

Elodie Gautier‐Veyret ◽

Jean‐François Jourdil ◽

...

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Bowel Diseases ◽

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

BMC Gastroenterology ◽

10.1186/s12876-017-0654-1 ◽

2017 ◽

Vol 17 (1) ◽

Cited By ~ 4

Author(s):

Lorant Gonczi ◽

Zsuzsanna Kurti ◽

Mariann Rutka ◽

Zsuzsanna Vegh ◽

Klaudia Farkas ◽

...

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Dose Intensification ◽

Adalimumab Therapy ◽

Bowel Diseases ◽

Faculty Opinions recommendation of Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735431918.793568132 ◽

2019 ◽

Author(s):

Ashish Patel

Keyword(s):

Drug Monitoring ◽

Biologic Agents ◽

Therapeutic Drug ◽

Bowel Diseases ◽

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2019.03.037 ◽

2019 ◽

Vol 17 (9) ◽

pp. 1655-1668.e3 ◽

Cited By ~ 48

Author(s):

Konstantinos Papamichael ◽

Adam S. Cheifetz ◽

Gil Y. Melmed ◽

Peter M. Irving ◽

Niels Vande Casteele ◽

...

Keyword(s):

Drug Monitoring ◽

Biologic Agents ◽

Therapeutic Drug ◽

Bowel Diseases ◽

P411 Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx002.536 ◽

2017 ◽

Vol 11 (suppl_1) ◽

pp. S286-S286

Author(s):

Z. Kurti ◽

M. Rutka ◽

Z. Vegh ◽

L. Gonczi ◽

K. Farkas ◽

...

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Dose Intensification ◽

Adalimumab Therapy ◽

Bowel Diseases ◽

Sa1975 Therapeutic Drug Monitoring Is a New Tool for Improving the Care of Patients Treated by antiTNF Alpha: Does This Apply to Children With Inflammatory Bowel Diseases?

Gastroenterology ◽

10.1016/s0016-5085(16)31463-9 ◽

2016 ◽

Vol 150 (4) ◽

pp. S421

Author(s):

Mallory Chavannes ◽

Prevost Jantchou ◽

France Gervais ◽

Robert Robitaille ◽

Valérie Marchand ◽

...

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Bowel Diseases ◽

Sa1981 Predictors of Loss of Response to Adalimumab Therapy; the Importance of Therapeutic Drug Monitoring in Inflammatory Bowel Diseases

Gastroenterology ◽

10.1016/s0016-5085(16)31469-x ◽

2016 ◽

Vol 150 (4) ◽

pp. S423

Author(s):

Zsuzsanna Kurti ◽

Zsuzsanna Vegh ◽

Petra A. Golovics ◽

Krisztina Gecse ◽

Lorant Gonczi ◽

...

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Loss Of Response ◽

Adalimumab Therapy ◽

Bowel Diseases ◽

P436 Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjx002.561 ◽

2017 ◽

Vol 11 (suppl_1) ◽

pp. S298-S298

Author(s):

M. Jimenez ◽

M. Sierra-Ausin ◽

N. Cano ◽

P. Suarez ◽

M. Fernandez-Gundin ◽

...

Keyword(s):

Clinical Practice ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Secondary Loss ◽

Loss Of Response ◽

Bowel Diseases ◽

P308. Predictors of loss of response to adalimumab therapy: the importance of therapeutic drug monitoring in inflammatory bowel diseases

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjw019.427 ◽

2016 ◽

Vol 10 (suppl 1) ◽

pp. S249.1-S249

Keyword(s):

Drug Monitoring ◽

Therapeutic Drug ◽

Loss Of Response ◽

Adalimumab Therapy ◽

Bowel Diseases ◽

Mo1835 - Soluble Madcam-1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Inflammatory Bowel Diseases under Vedolizumab: A Proof of Concept

Gastroenterology ◽

10.1016/s0016-5085(18)32799-9 ◽

2018 ◽

Vol 154 (6) ◽

pp. S-819

Author(s):

Stephane Paul ◽

Nicolas Williet ◽

Stephane Nancey ◽

Bernard Flourie ◽

Xavier Roblin

Keyword(s):

Retinoic Acid ◽

Drug Monitoring ◽

Therapeutic Drug ◽

Proof Of Concept ◽

Bowel Diseases ◽